Group 1 - The company has submitted a listing application to the Hong Kong Stock Exchange, with Agricultural Bank of China International, Minyin Capital, and Fosun International Capital as joint sponsors [1] - The company focuses on developing breakthrough therapies for cancer-related diseases, while also innovating drugs for viral and age-related diseases [1] - The product portfolio includes one commercialized product, Hanai Jia, two core products (CVL009 and CVL218), and a total of 16 drug candidates in development [1] Group 2 - Hanai Jia was commercialized on June 28, 2024, generating approximately RMB 34.7 million in sales during the first half of 2024 [1] - The company has established partnerships with leading pharmaceutical companies and employs a "one drug, multiple indications" research and development model [2]
甫康药业递表港交所 农银国际、民银资本等为保荐人